|Day Low/High||42.08 / 42.51|
|52 Wk Low/High||34.32 / 46.47|
Data to be presented at the 2019 Genitourinary Cancers Symposium
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc.
The Dow Jones Industrial Average falls as investors eye progress in this week's renewed U.S.-China trade talks.
Don't get too bearish, says Jim Cramer, but don't break discipline here. This is a perfectly reasonable decline.
Dramatic showdown or appeal for unity? Trump seeks to 'heal old wounds, build new coalitions.'
Selecting the creme de la creme of last year's top dividend dogs generated an average total return of 8.8%.
Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro® (dacomitinib) 45 mg, as monotherapy, be granted marketing authorization in...
Pfizer may be done with its two-month correction but the uptrend may not resume right away.
Kate Warne, investment strategist at Edward Jones, talked to TheStreet about what Boeing's report means for U.S. companies with exposure to China, Apple's beat and how the healthcare sector is looking.
Jim Cramer says that if expectations are too high, even a great quarter cannot save you from the wave of selling.
When the stock's inexpensive, hated and devoid of love -- that's when.
Pfizer posted solid fourth quarter earnings Tuesday but issued weaker-than-expected 2019 guidance as the exclusivity of its key epilepsy treatment Lyrica comes to and end.
The Dow Jones Industrial Average posted modest gains Tuesday ahead of financial results from tech bellwether Apple Inc.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
U.S. stock futures are mixed amid worries that a U.S. decision to pursue criminal charges against the chief financial officer of China's biggest tech company could stall progress in trade negotiations between the world's two biggest economies; the Fed begins a two-day meeting Tuesday; Apple, AMD, Verizon, Pfizer and 3M report earnings Tuesday; PG&E, the nation's largest utility, files for Chapter 11 bankruptcy protection.
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2018 and provided 2019 financial guidance.
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.
Global stocks were mixed Tuesday, with Wall Street futures drifting into the red, as investors worried that a U.S. decision to pursue criminal charges against the CFO of China's biggest tech company could stall progress in trade negotiations between the world's two biggest economies that are set to resume this week.
Eight important companies report earnings between Monday and Tuesday. Don't miss them.
U.S. equity futures fell sharply lower Monday as a profit warning from industrial equipment maker Caterpillar cast a pall over the busiest week of the fourth quarter earnings season as markets shifted focus to a series of major event risks and blue chip reports in the week ahead.
Global stocks drifted lower Monday as last week's late-hour rally on Wall Street, sparked by a surprise concession from President Donald Trump to end the 35-day government shutdown, fizzled in overnight trading as markets shifted focus to a series of major event risks and blue chip corporate earnings in the day ahead.
U.S. corporate earnings have come in largely ahead of analysts' forecasts in the first two weeks of the reporting season, according to data from Refinitiv, but the rate at which companies are beating estimates continues to slip below both near and longer-term averages, suggesting the fading impact of tax cuts, and concerns about slowing global growth, could dampen profits over the first half of the year.
Jim Cramer's plan for getting through the heart of earnings season next week.
Merck and Pfizer have been laggards so far in 2019. Technical warnings occurred on Dec. 4 when both set multiyear highs and both received downgrades.
Johnson & Johnson posted stronger-than-expected fourth quarter earnings Tuesday and forecast a modest increase in full year sales for 2019 that would take its top line past $81 billion.
Big pharma is shaping up to be a consolidating category in 2019.
Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.